Summary Alchemia Ltd (Alchemia) is a clinical stage biopharmaceutical company which focuses on the research and development drugs for the treatment of cancer and other therapeutic areas, such as cardiovascular disorders, and respiratory disorders. It develops its candidates based on its technology platforms, VAST, which is proprietary drug discovery platform and HyACT which is a cancer targeting technology. Its product pipeline comprises HA-Irinotecan, in Phase III trials for the treatment of metastatic colorectal cancer (mCRC) and in in Phase II trials for the treatment of small cell lung cancer (SCLC); HA-doxorubicin; HA-5FU; HA-monoclonal antibodies; and HA-chemotherapeutics. Alchemia has operations in the US and Australia through its subsidiaries. Alchemia is headquartered in South Melbourne, Victoria, Australia. Alchemia Ltd (ACL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The... Research Beam Model: Research Beam Product ID: 1747469 250 USD New
Alchemia Ltd (ACL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
 
 

Alchemia Ltd (ACL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

  • Category : Pharmaceuticals
  • Published On : July   2017
  • Pages : 28
  • Publisher : GlobalData
 
 
 
Summary

Alchemia Ltd (Alchemia) is a clinical stage biopharmaceutical company which focuses on the research and development drugs for the treatment of cancer and other therapeutic areas, such as cardiovascular disorders, and respiratory disorders. It develops its candidates based on its technology platforms, VAST, which is proprietary drug discovery platform and HyACT which is a cancer targeting technology. Its product pipeline comprises HA-Irinotecan, in Phase III trials for the treatment of metastatic colorectal cancer (mCRC) and in in Phase II trials for the treatment of small cell lung cancer (SCLC); HA-doxorubicin; HA-5FU; HA-monoclonal antibodies; and HA-chemotherapeutics. Alchemia has operations in the US and Australia through its subsidiaries. Alchemia is headquartered in South Melbourne, Victoria, Australia.

Alchemia Ltd (ACL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alchemia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alchemia Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alchemia Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alchemia Enters Into Collaboration Agreement with Merck Serono 11
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 11
Licensing Agreements 12
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 12
Equity Offering 13
Alchemia Completes Rights Offering Of Shares For US$2.8 Million 13
Alchemia Completes Private Placement Of Shares For US$10.4 Million 14
Audeo Oncology Withdraws IPO 15
Alchemia Completes Rights Issue Of Shares For US$5.4 Million 16
Alchemia Completes First Tranche Of Private Placement Of Shares For US$7.2 Million 17
Asset Transactions 19
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 19
Acquisition 20
Panther Biotech to Acquire Alchemia Oncology 20
Alchemia Ltd - Key Competitors 22
Key Employees 23
Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Jun 29, 2016: Alchemia Announces Resignation of Non-Executive Director 25
Mar 07, 2016: Alchemia Announces Appointment of Non - Executive Director 26
Feb 29, 2016: Alchemia Announces Appointment of Non - Executive Chairman and Retirement of Non - Executive Chairman 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Alchemia Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alchemia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alchemia Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Alchemia Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alchemia Enters Into Collaboration Agreement with Merck Serono 11
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 11
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 12
Alchemia Completes Rights Offering Of Shares For US$2.8 Million 13
Alchemia Completes Private Placement Of Shares For US$10.4 Million 14
Audeo Oncology Withdraws IPO 15
Alchemia Completes Rights Issue Of Shares For US$5.4 Million 16
Alchemia Completes First Tranche Of Private Placement Of Shares For US$7.2 Million 17
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 19
Panther Biotech to Acquire Alchemia Oncology 20
Alchemia Ltd, Key Competitors 22
Alchemia Ltd, Key Employees 23
Alchemia Ltd, Subsidiaries 24
List of Figures
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alchemia Ltd, Medical Devices Deals, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter